ARTICLE
27 February 2025

Court Extends TROs Enjoining Enforcement Of NIH Rate Change Within 22 Plaintiff States

DM
Duane Morris LLP

Contributor

Duane Morris LLP, a law firm with more than 900 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today's legal and business challenges.
Since taking office, the Trump Administration has taken steps to reshape the United States' federal funding infrastructure. One such action relates to the National Institutes of Health's ("NIH") rate change.
United States Massachusetts Food, Drugs, Healthcare, Life Sciences

Since taking office, the Trump Administration has taken steps to reshape the United States' federal funding infrastructure. One such action relates to the National Institutes of Health's ("NIH") rate change, imposing a 15% cap for indirect costs, for new grants and for existing grants awarded to institutions of higher education ("IHEs"). This rate change, which represents a drastic reduction from historical rates normally negotiated by grant recipients, will impact ongoing research programs and clinical trials, and will have a long-term impact on the United States' research infrastructure and abilities.

On February 10, 2025, the day the rate change was intended to go into effect, three lawsuits were filed in the U.S. District Court for the District of Massachusetts challenging the rate change. The lawsuits were filed by a group of stakeholders, including twenty-two states, thirteen universities, three university associations and five associations. Also on February 10, 2025, a district court judge granted two temporary restraining orders ("TROs"), enjoining enforcement of the rate change within the 22 Plaintiff states, and enjoining enforcement nationwide with respect to institutions. On February 21, 2025, following a hearing on the Plaintiffs' motions for injunctive relief, the district court ordered that the TROs entered on February 10, 2025, are extended and will remain in effect until further order of the Court.

Read more on the Duane Morris Life Sciences Law Blog.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More